Cybin announces positive cyb004 data demonstrating significant advantages over intravenous and inhaled dmt

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (cybin or the company), a biopharmaceutical company focused on progressing “psychedelics to therapeuticstm”, today announced positive preclinical data from a pharmacokinetic study evaluating its proprietary deuterated dimethyltryptamine (dmt) molecule, cyb004, delivered via inhalation. specifically, inhaled cyb004 demonstrated significant advantages over both iv dmt and inhaled dmt, including longer duration of action, and imp
CYBN Ratings Summary
CYBN Quant Ranking